# A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone o

Source: https://onco.cc/trials/nct07023289/  
OnCo record `nct07023289` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Telisotuzumab adizutecan in colorectal cancer, run by AbbVie, now recruiting.

## Summary

A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease is a phase 2 interventional study registered as NCT07023289 by AbbVie, with 140 participants planned, started 2025-09-02 and due to reach its primary completion in 2029-11. Interventions recorded: Telisotuzumab Adizutecan, Standard of Care. Conditions listed: Colorectal Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07023289
- Phase: 2
- Setting: A Phase 2, Randomized, Open-Label Study Comparing Telisotuzumab Adizutecan (ABBV-400) Monotherapy to the Current Standard of Care in Subjects With Post Adjuvant ctDNA Positive Colorectal Cancer and No Radiographic Evidence of Disease (NED)
- Sponsor: AbbVie
- Enrolled: 140

## Sources

- ClinicalTrials.gov NCT07023289: https://clinicaltrials.gov/study/NCT07023289

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)
- drugs: [Telisotuzumab adizutecan](https://onco.cc/drugs/telisotuzumab-adizutecan/)
- companies: [AbbVie (incl. ImmunoGen, Capstan)](https://onco.cc/companies/abbvie/)

---
JSON: https://onco.cc/api/v1/entities/nct07023289.json